MedTrace Logo

A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants

NCT02758392 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2017-01-23

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity of JNJ-61178104 following a single ascending Intravenous (IV) dose administration and a single Subcutaneous (SC) dose administration in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

JNJ-61178104 Intravenous

Participants will receive JNJ-61178104 Intravenously on Day 1.

DRUG

JNJ-61178104 Subcutaneous

Participants will receive JNJ-61178104 Subcutaneously on Day 1.

DRUG

Placebo

Participants will receive placebo on Day 1.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02758392 on ClinicalTrials.gov